These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 26689866)
1. Translation failure and medical reversal: Two sides to the same coin. Prasad V Eur J Cancer; 2016 Jan; 52():197-200. PubMed ID: 26689866 [TBL] [Abstract][Full Text] [Related]
2. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G; Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858 [TBL] [Abstract][Full Text] [Related]
3. [Phase III trials in oncology]. Imadalou K; Cvitkovic E Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944 [TBL] [Abstract][Full Text] [Related]
4. The role of nonrandomized trials in the evaluation of oncology drugs. Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488 [TBL] [Abstract][Full Text] [Related]
5. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. Karrison TG; Maitland ML; Stadler WM; Ratain MJ J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472 [TBL] [Abstract][Full Text] [Related]
6. Trial design for evaluation of novel targeted therapies. Farley J; Rose PG Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899 [TBL] [Abstract][Full Text] [Related]
7. Optimising the design of phase II oncology trials: the importance of randomisation. Ratain MJ; Sargent DJ Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773 [TBL] [Abstract][Full Text] [Related]
8. Performance of adaptive designs for single-armed phase II oncology trials. Kieser M; Englert S J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363 [TBL] [Abstract][Full Text] [Related]
9. Designs for randomized phase II clinical trials with two treatment arms. Hou W; Chang MN; Jung SH; Li Y Stat Med; 2013 Nov; 32(25):4367-79. PubMed ID: 23630064 [TBL] [Abstract][Full Text] [Related]
10. Ethical pitfalls in neonatal comparative effectiveness trials. Modi N Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328 [TBL] [Abstract][Full Text] [Related]
12. Optimal two-stage randomized multinomial designs for Phase II oncology trials. Sun LZ; Chen C; Patel K J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690 [TBL] [Abstract][Full Text] [Related]
13. When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial. De Rossi C; Brunello A; Jirillo G; Jirillo A Immunopharmacol Immunotoxicol; 2009; 31(1):1-4. PubMed ID: 19238693 [TBL] [Abstract][Full Text] [Related]
14. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. Wildiers H; Mauer M; Pallis A; Hurria A; Mohile SG; Luciani A; Curigliano G; Extermann M; Lichtman SM; Ballman K; Cohen HJ; Muss H; Wedding U J Clin Oncol; 2013 Oct; 31(29):3711-8. PubMed ID: 24019549 [TBL] [Abstract][Full Text] [Related]
15. Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial. Markman M Curr Oncol Rep; 2004 Nov; 6(6):421-2. PubMed ID: 15485610 [No Abstract] [Full Text] [Related]